CD-40 activating antibody (CP-870,893) in combination with cisplatin and pemetrexed in unresectable malignant mesothelioma: a phase Ib study to determine the maximum tolerated dose of CP-870,893
Phase of Trial: Phase I
Latest Information Update: 15 Jun 2017
At a glance
- Drugs CP 870893 (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Adverse reactions
- 18 Sep 2015 Status changed from active, no longer recruiting to completed according to the results in the Annals of Oncology.
- 18 Sep 2015 Results published in the Annals of Oncology.
- 18 Oct 2011 Status changed from not yet recruiting to active, no longer recruiting according to Australian New Zealand Clinical Trials Registry record.